scholarly journals Varying expression levels of colony stimulating factor receptors in disease states and different leukocytes

2000 ◽  
Vol 32 (4) ◽  
pp. 210-215 ◽  
Author(s):  
Kyo Young Lee ◽  
Byung-Gyu Suh ◽  
Jong Wan Kim ◽  
Won Bae Lee ◽  
So-Young Kim ◽  
...  
Keyword(s):  
Colony Stimulating Factor ◽  
Expression Levels ◽  
Disease States ◽  
Stimulating Factor

scholarly journals Granulocyte Colony-Stimulating Factor Restored Impaired Spermatogenesis and Fertility in an AML-Chemotherapy Mice Model

2021 ◽  
Vol 22 (20) ◽  
pp. 11157
Author(s):  
Yulia Michailov ◽  
Ali AbuMadighem ◽  
Eitan Lunenfeld ◽  
Joseph Kapelushnik ◽  
Mahmoud Huleihel
Keyword(s):  
Male Fertility ◽  
Inflammatory Cytokine ◽  
Sperm Parameters ◽  
Seminiferous Tubules ◽  
Testis Weight ◽  
Post Injection ◽  
Colony Stimulating Factor ◽  
Expression Levels ◽  
First Time ◽  
Stimulating Factor

Leukemia and treatment of male patients with anticancer therapy (aggressive chemotherapy and/or radiotherapy) may lead to infertility or even permanent male sterility. Their mechanisms of spermatogenesis impairment and the decrease in male fertility are not yet clear. We showed that under acute myeloid leukemia (AML) conditions, alone and in combination with cytarabine (CYT), there was significant damage in the histology of seminiferous tubules, a significant increase in apoptotic cells of the seminiferous tubules, and a reduction in spermatogonial cells (SALL and PLZF) and in meiotic (CREM) and post-meiotic (ACROSIN) cells. In addition, we showed a significant impairment in sperm parameters and fertilization rates and offspring compared to control. Our results showed a significant decrease in the expression of glial cell line-derived neurotrophic factor (GDNF), macrophage colony-stimulating factor (MCSF) and stem cell factor (SCF) under AML conditions, but not under cytarabine treatment compared to control. In addition, our results showed a significant increase in the pro-inflammatory cytokine interleukin-1 (IL-1) alpha in whole testis homogenates in all treatment groups compared to the control. Increase in IL-1 beta level was shown under AML conditions. We identified for the first time the expression of GCSF receptor (GCSFR) in sperm cells. We showed that GCSF injection in combination with AML and cytarabine (AML + CYT + GCSF) extended the survival of mice for a week (from 6.5 weeks to 7.5 weeks) compared to (AML + CYT). Injection of GCSF to all treated groups (post hoc), showed a significant impact on mice testis weight, improved testis histology, decreased apoptosis and increased expression of pre-meiotic, meiotic and post- meiotic markers, improved sperm parameters, fertility capacity and number of offspring compared to the controls (without GCSF). GCSF significantly improved the spermatogonial niche expressed by increased the expression levels of testicular GDNF, SCF and MCSF growth factors in AML-treated mice and (AML + CYT)-treated mice compared to those groups without GCSF. Furthermore, GCSF decreased the expression levels of the pro-inflammatory cytokine IL-12, but increased the expression of IL-10 in the interstitial compartment compared to the relevant groups without GCSF. Our results show for the first time the capacity of post injection of GCSF into AML- and CYT-treated mice to improve the cellular and biomolecular mechanisms that lead to improve/restore spermatogenesis and male fertility. Thus, post injection of GCSF may assist in the development of future therapeutic strategies to preserve/restore male fertility in cancer patients, specifically in AML patients under chemotherapy treatments.

scholarly journals Granulocyte Colony-Stimulating Factor and Its Potential Application for Skeletal Muscle Repair and Regeneration

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Craig R. Wright ◽  
Alister C. Ward ◽  
Aaron P. Russell
Keyword(s):  
Skeletal Muscle ◽  
Tissue Repair ◽  
Therapeutic Agent ◽  
Strenuous Exercise ◽  
Muscle Repair ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Disease States ◽  
Tissue Repair And Regeneration ◽  
Stimulating Factor

Granulocyte colony-stimulating factor (G-CSF) was originally discovered in the context of hematopoiesis. However, the identification of the G-CSF receptor (G-CSFR) being expressed outside the hematopoietic system has revealed wider roles for G-CSF, particularly in tissue repair and regeneration. Skeletal muscle damage, including that following strenuous exercise, induces an elevation in plasma G-CSF, implicating it as a potential mediator of skeletal muscle repair. This has been supported by preclinical studies and clinical trials investigating G-CSF as a potential therapeutic agent in relevant disease states. This review focuses on the growing literature associated with G-CSF and G-CSFR in skeletal muscle under healthy and disease conditions and highlights the current controversies.

scholarly journals Potential Manipulations to Restore Aberrant Myelopoiesis: The Role of New Colony-Stimulating Factors and other Agents

1992 ◽  
Vol 3 (suppl b) ◽  
pp. 76-83
Author(s):  
James J Rusthoven
Keyword(s):  
Single Agent ◽  
Colony Stimulating Factor ◽  
Colony Stimulating Factors ◽  
Gm Csf ◽  
Disease States ◽  
Combination Studies ◽  
Therapeutic Alternatives ◽  
Stimulating Factor ◽  
Established Infection

A rapidly growing number of new recombinant human colony-stimulating factors (CSFs) are entering various phases of clinical testing. With the recent approval of granulocyte colony-stimulating factor (G-CSF) and granulocytemacrophage colony-stimulating factor (GM-CSF) for clinical use, newer CSFs will be developed for a widening spectrum of disease states singularly and in combination with other CSFs. Interleukin (IL)-3 is being tested in early clinical trials, and combination studies with G-CSF and GM-CSF are to follow soon. lL-6 presently is in animal model testing, but already shows promise of amplifying the restorative capabilities of IL-3. IL-4 , GM-CSF and others. As a single agent, IL-6 may be instrumental in clarifying disease processes and therapeutics in diseases ranging from multiple myeloma to glomerulonephritis. Agents such as WR-2721 which appear to protect early progenitors with or without proliferative effects likely will add another dimension to the therapeutic alternatives for restoring aberrant myelopoiesis. The range of potential clinical application for new CSFs rapidly is expanding beyond oncology to include diseases where infection prevention or therapy against established infection is the prime target of treatment.

Sign in / Sign up

Export Citation Format

Share Document